Compare Lamb Weston Holdings Inc (LW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs TG Therapeutics Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.77 (market cap $6.81B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and TG Therapeutics Inc for 16 Days on average.
| LW | TGTX | |
|---|---|---|
Market Cap | $6.81B | $8.16B |
Volume | 4,638,686 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $59.06 |
52-Week Low | $38.48 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | $10.61B | $8.37B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $47.87, down 0.46% on the day, with a bullish technical signal supported by moving averages. The company shows consistent earnings beats in recent quarters, with Q3 2026 EPS of $0.75 exceeding expectations of $0.587. Revenue reached $6.45 billion in 2025, though net income margin declined to 3.85%. Analyst consensus price target stands at $53.71, representing 12% upside potential from current levels.
The stock presents a mixed outlook with strong technical momentum and earnings consistency offset by margin compression and elevated valuation at 27x P/E. Key risks include competitive pressures in the food industry and ongoing margin challenges. Institutional sentiment leans cautious with 63% hold ratings, suggesting limited near-term catalysts despite the technical bullish setup.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
